Monoclonal antibodyFDA-approvedFirst-line
Cetuximab
How it works
Blocks the epidermal growth factor receptor (EGFR), a protein that can drive cancer growth. By blocking EGFR, the cancer cells are less likely to grow and divide.
Cancer types
Melanoma— EGFR-expressing
Colorectal Cancer— Wild-type KRAS
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Butyrate May Reduce Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Machine Learning Predicts Cancer Treatment Outcomes | Colorectal Cancer | phase-3 | Higher toxicity clusters were associated with improved overall survival and progression-free survival outcomes (adjusted hazard ratios ranging from 2.21 to 4.36) and higher CET concentrations (p = .003). | Source → |
| RAS Mutations in Blood Linked to Poorer Outcomes in Colorectal Cancer | Colorectal Cancer | phase-2 | The presence of ctDNA RAS mutations at any time point was significantly associated with poorer progression-free survival (adjusted HR = 2.24, P = .02). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.